• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

New approaches to assess topical corticosteroid bioequivalence: pharmacokinetic evaluation.

作者信息

Pershing L K

机构信息

Division of Dermatology, University of Utah Health Sciences Center, Salt Lake City 84132.

出版信息

Int J Dermatol. 1992 Oct;31 Suppl 1:14-20. doi: 10.1111/j.1365-4362.1992.tb04007.x.

DOI:10.1111/j.1365-4362.1992.tb04007.x
PMID:1428461
Abstract

An ideal method for measuring the bioavailability of topical corticosteroids should be simple, accurate, and adaptable to a variety of settings and should not require extensive special training to perform. Drug uptake into the stratum corneum, measured by tapestripping, is correlated with the pharmacodynamic response of skin blanching, observed in the vasoconstrictor assay. Differences in stratum corneum drug uptake can be objectively quantitated as a function of time, occlusion, dose applied, and vehicle. Tapestripping measurements are reproducible within individual subjects, but large interindividual variabilities may exist. The chromameter, a new technology, objectively quantitates color numerically and can be used to measure skin blanching as part of the pharmacodynamic response to topical corticosteroids. The chromameter offers an easy, objective method with which to quantitate the pharmacodynamic response of topical corticosteroids. Both methods allow a more mechanistic approach than currently used methods to investigate topical drug pharmacokinetics and pharmacodynamics.

摘要

相似文献

1
New approaches to assess topical corticosteroid bioequivalence: pharmacokinetic evaluation.
Int J Dermatol. 1992 Oct;31 Suppl 1:14-20. doi: 10.1111/j.1365-4362.1992.tb04007.x.
2
Topical 0.050% betamethasone dipropionate. Pharmacokinetic and pharmacodynamic dose-response studies in humans.外用0.050%丙酸倍他米松。人体药代动力学和药效学剂量反应研究。
Arch Dermatol. 1994 Jun;130(6):740-7. doi: 10.1001/archderm.130.6.740.
3
Circadian activity of topical 0.05% betamethasone dipropionate in human skin in vivo.0.05%丙酸倍他米松在人体皮肤中的昼夜活性(体内研究)
J Invest Dermatol. 1994 May;102(5):734-9. doi: 10.1111/1523-1747.ep12376062.
4
Pharmacodynamics and dermatopharmacokinetics of betamethasone 17-valerate: assessment of topical bioavailability.倍他米松 17-戊酸酯的药效学和皮肤药代动力学:局部生物利用度评估
Br J Dermatol. 2009 Mar;160(3):676-86. doi: 10.1111/j.1365-2133.2008.08757.x. Epub 2008 Sep 6.
5
Feasibility of measuring the bioavailability of topical betamethasone dipropionate in commercial formulations using drug content in skin and a skin blanching bioassay.利用皮肤中的药物含量和皮肤变白生物测定法测定市售制剂中丙酸倍他米松局部生物利用度的可行性。
Pharm Res. 1992 Jan;9(1):45-51. doi: 10.1023/a:1018975626210.
6
Analysis of chromameter results obtained from corticosteroid-induced skin blanching assay: comparison of visual and chromameter data.对皮质类固醇诱导的皮肤变白试验所得色差计结果的分析:视觉数据与色差计数据的比较
Eur J Pharm Biopharm. 1999 May;47(3):261-7. doi: 10.1016/s0939-6411(98)00094-0.
7
Topical corticosteroids: quality control considerations.外用糖皮质激素:质量控制考量
Int J Dermatol. 1992 Oct;31 Suppl 1:34-7. doi: 10.1111/j.1365-4362.1992.tb04011.x.
8
Evaluation of the proposed FDA pilot dose-response methodology for topical corticosteroid bioequivalence testing.对美国食品药品监督管理局(FDA)提议的用于局部用皮质类固醇生物等效性测试的中剂量-反应方法的评估。
Pharm Res. 1997 Mar;14(3):303-8. doi: 10.1023/a:1012089803281.
9
Bioequivalence Methodologies for Topical Drug Products: In Vitro and Ex Vivo Studies with a Corticosteroid and an Anti-Fungal Drug.局部用药品的生物等效性方法:皮质类固醇和抗真菌药物的体外和离体研究
Pharm Res. 2017 Apr;34(4):730-737. doi: 10.1007/s11095-017-2099-1. Epub 2017 Jan 17.
10
The vasoconstrictor assay in bioequivalence testing: practical concerns and recent developments.生物等效性测试中的血管收缩剂测定:实际问题与最新进展
Int J Dermatol. 1992 Oct;31 Suppl 1:26-8. doi: 10.1111/j.1365-4362.1992.tb04009.x.

引用本文的文献

1
FDA critical path initiatives: opportunities for generic drug development.美国食品药品监督管理局关键路径计划:仿制药开发的机遇
AAPS J. 2008;10(1):103-9. doi: 10.1208/s12248-008-9010-2. Epub 2008 Feb 20.